MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: BioPharmaceuticals _ Biotechnology, Genomics, Genetics, Bioinformatics, Biomanufacturing & Personalized Medicine
*Biotechnology: Key Issues
*Key Terms: Biotechnology
Phage
Parents
*Key Terms: Biotechnology
BioTechnology
Infectious Disease
Children
*Architects: Infectious Disease _ Bacteriology_Antibiotics
*Funding: NIH_NIDCR
*Proprietary phage display screening platform which directs the evolution of bicyclic peptides to rapidly and empirically generate optimized novel drug candidates
2011: Phagenesis closes €7m series B funding round (2011)
2020: Adaptive Phage Therapeutics lands $10.2M DOD contract for war on superbugs
2020: ArcherDX, Geneoscopy, Phagenesis win FDA breakthrough device designations
2021: Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research
2021: Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases – Adaptive Phage Therapeutics
2021: Adaptive Phage Therapeutics Expands Board Following $40.75 million Series B Financing Led by Deerfield Management
2022: CF Foundation awards up to $5 million for phage therapy clinical trial
2022: Gaithersburg’s Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial_Biohealth Innovation
2023: Adaptive Phage Therapeutics, Inc. cut 22 jobs, or 23% of its total headcount, to shift its focus to its clinical trials and extend its cash runway
2028: NIDCR_NOSI_NIDCR Support for Research on Understanding Phage Biology in the Oral Cavity
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections.
Adaptive Phage Therapeutics Inc.
An increased understanding of the role of bacteriophage in the oral cavity could lead to the development and use of phage therapy.
APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage.
BiomX Inc. (NYSE: PHGE)*
By restoring swallowing control, Phagenesis aims to treat the dysphagia that prevents removal of breathing tubes in some tracheostomized patients.
Cambridge Antibody Technology, or CAT, was the UK biotechnology group of companies whose success was based mainly on its ability to generate antibody therapeutics, primarily using phage display, and the subsequently acquired ribosome display, technology
Can deliver specific phages for human and animal health and food safety applications that are timely, cost effective, better for the environment and highly effective on exposed bacteria.
Finance & Acquisitions: Adaptive Phage
Gregory Merrill, CEO, Adaptive Phage Therapeutics, co-founder and CEO of Brain Sentry, Immersion (2020)
Intralytix developing proprietary PhageSelector™ program, big data, and manufacturing know-how along with machine learning to advance an artificial intelligence (AI)-based universal manufacturing platform, the PhageEngine™, to deliver methods for producing high titer, high quality bacteriophage preparations suitable for clinical applications.
Intralytix, Inc.
Key People: Adaptive Phage
Organization & Developments: Adaptive Phage
Patented technology creates phages that target specific bacteria, to treat virtually any bacterial infection or disease.
Phage Biocontrol
Phage dispaly
PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale.
Phagelux (Canada) Inc.
Phagenesis
PhagePro, Inc.
PhageVax
PhageVax, Inc
Targeting antibiotic resistance genes in Vibrio cholerae using a phage-encoded CRISPR-Cas system to improve efficacy of phage prophylaxis
Unlocks the potential of nature’s elegant and harmless anti-bacterial solution - phages.